章雄文

章雄文，男，博士，華東師範大學化學與分子工程學院教授。

基本介紹

• 中文名：章雄文
• 職業：教師
• 畢業院校：中國科學院
• 學位/學歷：博士
• 專業方向：化學與分子工程
• 任職院校：華東師範大學

研究方向

從事分子腫瘤藥理學及分子靶向抗腫瘤新藥研發。 1.小分子激酶抑制劑抗腫瘤新藥研發 2.雙/多靶點抗腫瘤新藥研發 3.抗腫瘤惡病質新藥研發 4.腫瘤多藥耐藥逆轉劑新藥研發

個人經歷

1985年畢業於福建醫科大學醫療系獲學士學位，1991年畢業於福建醫科大學獲腫瘤藥理學專業碩士學位，1999年畢業於中科院上海藥物研究所獲分子腫瘤藥理學專業博士學位。1999-2002年在美國田納西大學和St. Jude兒童研究醫院從事博士後研究工作。2002年加入中科院上海藥物研究所國家新藥重點研究室腫瘤藥理組研究員。2006年加入亞盛醫藥研發有限公司任生物部總監。2007年加入羅氏研發中心（中國），先後任物篩選技術部主任、分子腫瘤部主任、體內藥理學部主任等職。2013年加入華東師範大學。

學術成果

在高質量雜誌上發表研究文章80篇（SCI收錄71篇），申請專利24項（14項授權）。先後主持多項國家科技部863和973課題及國家自然科學基金項目。參與發明一個1.1類新藥進入臨床，領導完成數個抗腫瘤新藥臨床前研發的完整過程，並領導參與新藥臨床I/IIa期實驗。 代表性論文（Selected Research Publications）： 1.Dual VEGFR2 and Aurora kinase inhibitor R1498 as a novel treatment for gastric cancer and hepatocellular cancer.PLOS ONE2013 2.Targeting cadherin-17 inactivates Ras/Raf/MEK/ERK signaling and inhibits cell proliferation in gastric cancer.PLOS ONE2014 3.Targeting NEK2 as a promising therapeutic approach for cancer treatment.Cell Cycle2016 4.Design, Synthesis, and Biological Evaluation of New Cathepsin B-Sensitive Camptothecin Nanoparticles Equipped with a Novel Multifuctional Linker.Bioconjugate Chemistry2016 5.NIR fluorescent DCPO glucose analogues and their application in cancer cell imaging.RSC Adv2016 6.Preclinical activity of MBM-5 in gastrointestinal cancer by inhibiting NEK2 kinase activity.Oncotarget2016 7.Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases.J Exp Clin Cancer Res2016 8.Characterization of a near-infrared fluorescent dcpo-tagged glucose analogue for cancer cell imaging.J Photoch Photobio B2017 9.Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as noveland potent Nek2 inhibitors with in vitro and in vivo antitumor activities.Eur J Med Chem.2017 10.ES2 enhances the efficacy of chemotherapeutic agents in ABCB1-overexpressing cancer cells in vitro and in vivo.Pharmacol Res2018 Mar; 11.Tumor-targeting efficacy of aBF211 prodrug through hydrolysis by fibroblast activation protein-α.Acta Pharmacol Sin2018 Mar 12.Pyrrolidine Dithiocarbamate (PDTC) Attenuates Cancer Cachexia by Affecting Muscle Atrophy and Fat Lipolysis.Front Pharmacol2017 Dec 13.Design and synthesis of aryloxypropanolamine as β3-adrenergic receptor antagonist in cancer and lipolysis.Eur J Med Chem.2018 Apr 14.Synthesis and evaluation of novel dimethylpyridazine derivatives as hedgehog signaling pathway inhibitors.Bioorg Med Chem.2018 15.L-4, a Well-Tolerated and Orally Active Inhibitor of Hedgehog Pathway, Exhibited Potent Anti-tumor Effects Against Medulloblastoma in vitro and in vivo.Front Pharmacol2019 Feb 16.SiBaoChongCao exhibited anti-fatigue activities and ameliorated cancer cachexia in mice.RSC Adv.2019 Jun;